AWS
ADCT icon

Atria Wealth Solutions’s ADC Therapeutics ADCT Stock Holding History

Atria Wealth Solutions’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$28.2K – 1467
2025
Q1 		$28.2K Buy
+20,000
New +$34K ﹤0.01% 1838

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Atria Wealth Solutions's ADCT Position: Q2 2025 in Review

Atria Wealth Solutions sold out of ADC Therapeutics (ADCT) in Q2 2025, closing a stake of 20,000 shares — an estimated $28.2K sold.

Atria Wealth Solutions first reported a position in ADCT in Q1 2025 and held it in 1 quarter. The position peaked at $28.2K in Q1 2025. 86 funds tracked by Wall St. Rank hold ADCT as of Q2 2025.

  • Atria Wealth Solutions reported no remaining ADC Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Atria Wealth Solutions sold 20,000 ADC Therapeutics shares in Q2 2025, an estimated $28.2K.
  • Atria Wealth Solutions first reported a position in ADC Therapeutics in Q1 2025 and held it in 1 quarter.
  • Atria Wealth Solutions's ADC Therapeutics position peaked at $28.2K in Q1 2025.
  • 86 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2025.

Based on Atria Wealth Solutions's 13F filing for Q2 2025, filed 25 Jul 2025.